| P50 | author | Masaaki Kondo | Q88403207 |
| | Kazushi Numata | Q90960367 |
| P2093 | author name string | Katsuaki Tanaka | |
| | Hiroyuki Fukuda | |
| | Akito Nozaki | |
| | Shin Maeda | |
| | Koji Hara | |
| | Makoto Chuma | |
| P2860 | cites work | Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma | Q57214428 |
| | Impact of intra-individual molecular heterogeneity in personalized treatment of hepatocellular carcinoma | Q57756620 |
| | Postprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancer | Q26829939 |
| | Management of hepatocellular carcinoma: An update | Q27860530 |
| | Sorafenib in advanced hepatocellular carcinoma | Q27861075 |
| | Compacted sewage sludge as a barrier for tailings: the heavy metal speciation and total organic carbon content in the compacted sludge specimen | Q28540176 |
| | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial | Q29547903 |
| | Hepatocellular carcinoma | Q29616359 |
| | Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib | Q33411190 |
| | Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis | Q33778970 |
| | Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial | Q34663499 |
| | Rapid vascular regrowth in tumors after reversal of VEGF inhibition | Q35052385 |
| | CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment | Q35193958 |
| | Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. | Q35597241 |
| | Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. | Q36944493 |
| | Second-line treatment in advanced pancreatic cancer: a comprehensive analysis of published clinical trials | Q37032865 |
| | Design and endpoints of clinical trials in hepatocellular carcinoma. | Q37162908 |
| | Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial | Q37387978 |
| | Modified RECIST (mRECIST) assessment for hepatocellular carcinoma | Q37696396 |
| | Advances in targeted therapies for hepatocellular carcinoma in the genomic era. | Q38521011 |
| | Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial | Q38785510 |
| | TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON. | Q40129689 |
| | Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib. | Q40461237 |
| | Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C). | Q41696179 |
| | Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma | Q41898172 |
| | Efficacy of sorafenib beyond first progression in patients with metastatic hepatocellular carcinoma | Q43454599 |
| | Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design | Q43950860 |
| | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | Q44681461 |
| | Postprogression survival for first-line chemotherapy in patients with advanced gastric cancer | Q45722661 |
| | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | Q45980006 |
| | Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan. | Q51266416 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 5728946 | |
| P577 | publication date | 2017-06-22 | |
| P1433 | published in | Gastroenterology research and practice | Q26853898 |
| P1476 | title | Treatment of Advanced Hepatocellular Carcinoma after Failure of Sorafenib Treatment: Subsequent or Additional Treatment Interventions Contribute to Prolonged Survival Postprogression | |
| P478 | volume | 2017 | |